Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator ...

GRIFOLS transfer bags are used for sterile preservation and administration of blood components. Blood components can be obtained, stored and preserved without contact with the environment ensuring ...

Grifols plans to release Phase III results of its long-term albumin treatment designed to increase survival time in patients with decompensated cirrhosis and ascites in 2024, says chief scientific ...

Grifols shares plunged by a further 14% on Wednesday following publication of another report from short seller Gotham City Research, raising additional questions about the Barcelona medicine maker ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

MADRID (Reuters) - U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical ...

Shares in Spanish pharma group Grifols have plummeted after UK-based hedge fund Gotham City Research issued a report claiming it has fraudulently manipulated its financial reporting by not ...

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in court.

Grifols’ repository of PD plasma samples is just a fraction of the more than 100 million samples the company has collected for nearly 15 years. Its proprietary bank is one of the world’s ...

(Bloomberg) -- Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...